Kilitch Drugs (India) Ltd Stock Analysis

BSE: 524500 | NSE: KILITCH | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 05-Dec-2022 18:01
162.40 1.25 (0.78%)

DeciZen - Make an Informed Decision on Kilitch Drugs(India)

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Fair

3. Price Trend

Kilitch Drugs(India) Price Chart

P/E Ratio (SA) :
20.16
Market Cap :
251.1 Cr.
52-wk low :
144.3
52-wk high :
276.4
Bole Toh?

1. Is Kilitch Drugs (India) Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.

2. Is Kilitch Drugs (India) Ltd undervalued or overvalued?

The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Kilitch Drugs (India) Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kilitch Drugs (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Kilitch Drugs(India):

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kilitch Drugs (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 2.9%-1.8%-0.1%-1.9%0.4%4.1%9.2%1.7%3.1%5.3%-
Value Creation Index -0.8-1.1-1.0-1.1-1.0-0.7-0.3-0.9-0.8-0.6-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 33.214.9192128.150.596.460.870105109
YoY Gr. Rt. %--55.1%27.7%10.5%33.9%79.3%91.1%-37%15.2%50.2%-
Adj EPS 2.6-1.6-0.1-1.70.33.68.51.3368
YoY Gr. Rt. %--161.4%NANANA1332%136.3%-84.2%123.1%100.7%-
BVPS (₹) 77.589.889.688.188.992.897.797.5104.9112.4119.6
Adj Net Profit 3.5-2.2-0.2-2.30.34.9132.14.69.412
Cash Flow from Ops. 1.5-31.1-7.6180.6-1.37.47.36.15.2-
Debt/CF from Ops. 00001.1-0.61.31.72.43.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.7%30.2%2.9%50.2%
Adj EPS 9.6%88.8%-10.8%100.7%
BVPS 4.24.84.87.1
Share Price 16.1% 13.6% 12.4% 3.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 3-1.8-0.1-1.90.33.99.21.435.56.9
Op. Profit Mgn % -11.1-25.2-6-150.511.1171.97.611.311.8
Net Profit Mgn % 10.5-14.4-0.8-10.71.29.813.53.46.68.911.5
Debt to Equity 0000000.10.10.10.10
Working Cap Days 184632725536280193173373364299355
Cash Conv. Cycle 8211717024416386641075939172

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 6.90%

Sales growth is good in last 4 quarters at 30.01%

Sales growth has been subdued in last 3 years 2.93%

Net Profit has been subdued in last 3 years -10.82%

Latest Financials - Kilitch Drugs (India) Ltd.

Standalone Consolidated
TTM EPS (₹) 8 5.5
TTM Sales (₹ Cr.) 109 135
BVPS (₹.) 119.6 92.9
Reserves (₹ Cr.) 171 129
P/BV 1.35 1.75
PE 20.16 29.65
From the Market
52 Week Low / High (₹) 144.30 / 276.40
All Time Low / High (₹) 0.75 / 276.40
Market Cap (₹ Cr.) 251
Equity (₹ Cr.) 15.6
Face Value (₹) 10
Industry PE 37.8

Management X-Ray of Kilitch Drugs(India) :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.970.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Kilitch Drugs(India)

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Kilitch Drugs (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Kilitch Drugs(India) on 05-Dec-2022 18:01 is : 162.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Dec-2022 18:01 the market cap of Kilitch Drugs(India) stood at ₹ 251.1.
The latest PE ratio of Kilitch Drugs(India) as of 05-Dec-2022 18:01 is 20.16.
The latest PB ratio of Kilitch Drugs(India) as of 05-Dec-2022 18:01 is 1.35
The 52-week high of Kilitch Drugs(India) is ₹ 276.4 and the 52-week low is ₹ 144.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Kilitch Drugs(India) is ₹ 108.6 ( Cr.) .

About Kilitch Drugs (India) Ltd

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now